The cover shows a section of a primary tumor at diagnosis from a patient with metastatic colon cancer who failed a bevacizumab-containing regimen as first-line treatment. Immunohistochemical staining shows HOXB9 expression in tumor cells. For details, see the article by Carbone and colleagues on page 4312 of this issue.